1. Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies
   Véronique Diéras et al, 2005, Clinical Cancer Research CrossRef
2. Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel
   Zoya N. Demidenko et al, 2005, Cancer Research CrossRef